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IMPORTANCE There is a concern thatHelicobacter pylori therapy containing clarithromycin
might be associated with acute neuropsychiatric events.
OBJECTIVE To examine the association betweenH pylori therapy containing clarithromycin
and acute neuropsychiatric events.
DESIGN, SETTING, AND PARTICIPANTS A self-controlled case series studywas conducted using
the Clinical Data Analysis and Reporting System database in Hong Kong to explore any
association. The exposure of interest wasH pylori therapy containing clarithromycin in the
outpatient setting. Study patients, 18 years or older at cohort entry, must have had both
exposure toH pylori therapy containing clarithromycin and their first recorded
neuropsychiatric events between January 1, 2003, and December 31, 2012. A post hoc nested
case-control analysis was also performed in patients receivingH pylori therapy containing
clarithromycin.
MAIN OUTCOMES ANDMEASURES The primary outcomewas composite neuropsychiatric
events, while secondary outcomes were psychotic events and cognitive impairment. Risk
periods in the self-controlled case series analysis were defined as 14-day preexposure period,
current use (days 1-14 since prescription start date) and recent use (days 15-30). Age-adjusted
incidence rate ratios (IRR) were estimated using the conditional Poisson regression.
RESULTS Of 66 559 patients who had at least 1 outpatient prescription ofH pylori therapy
containing clarithromycin. Their mean (SD) age at cohort entry was 50.8 (14.8 years); their
mean age at first exposure was 55.4 (14.8) years, and 30910weremale (46.4%). A total of
1824 patients had their first recorded composite neuropsychiatric events during the study
period. An increased IRR of 4.12 (35 composite neuropsychiatric events during 72
person-years; 95% CI, 2.94-5.76) during current use was observed but not in recent use (9
events during 82 person-years; IRR, 0.95; 95% CI, 0.49-1.83) and 14-day preexposure period
(14 events during 72 person-years; IRR, 1.63; 95% CI, 0.96-2.77) vs baseline (1766 events
during 16 665 person-years). Similarly, both the risk of psychotic events and cognitive
impairment increased during current use vs baseline, although this subsequently returned to
baseline incidence levels during recent use. The crude absolute risks of composite
neuropsychiatric events, psychotic events, and cognitive impairment during current use were
0.45, 0.12, and 0.12 per 1000 prescriptions, respectively. The nested case-control analysis
also gave similar results to that of the self-controlled case series analysis.
CONCLUSIONS AND RELEVANCE This study shows evidence of a short-term increased risk of
neuropsychiatric events associated withH pylori therapy containing clarithromycin.
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C larithromycin isused for the treatmentof respiratory in-fections, includingcommunity-acquiredpneumonia.1 Itisalsocommonlyprescribedincombinationwithamoxi-
cillin or metronidazole, plus proton pump inhibitors (PPIs) as
a first-line standard treatment for Helicobacter pylori eradi-
cation.2Amongpotentialadverseeventsassociatedwiththeuse
of clarithromycin, neuropsychiatric symptoms were de-
scribed in 1995 when 2 patients with AIDS developed delu-
sions,anxiety, andagitation following treatmentwithclarithro-
mycinforMycobacteriumaviumcomplex infection.3Thereafter,
several case reports raised concerns that clarithromycinmight
be associatedwith neuropsychiatric events in patients with or
without other long-term comorbidities, such as renal disease,
hypertension, and obstructive airway disease.4-16 One litera-
ture review reported 38 adult patients with clarithromycin-
inducedneuropsychiatric eventsalsosuggestingapossible link
betweenclarithromycinandneuropsychiatric events.17Mostof
the reported neuropsychiatric symptoms were related to psy-
choticmanifestationsandcognitivedisturbances.17 In these re-
ports, the neuropsychiatric symptoms seemed to be resolved
afterdiscontinuationofclarithromycin treatment.Notably, cla-
rithromycinwas frequently reported tobeassociatedwithma-
nia basedonunpublished reports from theWorldHealthOrga-
nization and the US Food and Drug Administration.18
Apart from clarithromycin monotherapy, neuropsychiat-
ric symptoms were also observed in patients receiving H
pylori therapy containing clarithromycin.19-25 Despite signal
detection implicating clarithromycin as the causative agent of
neuropsychiatric events, to our knowledge, no population-
based study has been conducted to assess and evaluate the
neuropsychiatric risk associated with clarithromycin.
Patients receiving clarithromycinmighthave ahigher risk
of severe acute infections than those prescribed amoxicillin
or other penicillins. Owing to different underlying neuropsy-
chiatric risks, indication bias might result in findings of non-
causal associations. In our previous work, we examined the
association between cardiovascular events and clarithromy-
cin using the cohort of H pylori therapy containing clarithro-
mycin in a secondary analysis to reduce confounding.26Using
similar methods, we further explored the safety consider-
ations of clarithromycin in this study by investigating the as-
sociation between H pylori therapy containing clarithromy-
cin and acute neuropsychiatric events.
Methods
Data Sources
The study protocol was approved by the institutional review
boardof theUniversityofHongKong/HospitalAuthorityHong
KongWest Cluster. The data were retrieved from the Clinical
DataAnalysis andReporting Systemdatabase,which is devel-
oped andmanaged by theHospital Authority inHongKong.27
The Hospital Authority currently manages 42 public hospi-
talsand institutions,47specialistoutpatientclinics,and73gen-
eral outpatient clinics.28 More than 7 million local residents
have access to these primary, secondary, and tertiary public
health care services through 7 hospital clusters.27 In the Hos-
pital Authority, the Clinical Management System was estab-
lished as a clinicalworkstation to provide access towards and
ambulatory settings, aswell as laboratory, radiology, andphar-
macy systems in public hospitals and clinics. The clinical in-
formation is directly recorded into the Clinical Management
System by clinicians and other health care professionals. The
health records in theClinicalManagementSystemare thenrou-
tinely transferred to the Clinical Data Analysis and Reporting
System for audit and research purposes. Since 1993, the elec-
tronic health records in theClinical DataAnalysis andReport-
ing System have included patient demographics and clinical
data such as diagnosis, operation, prescription use, accident
and emergency visits, and outpatient and inpatient visits. A
unique patient identifier is generated for each individual pa-
tient to link all medical records. To protect patient confiden-
tiality, allmedical records are anonymized. This database has
beenused to conduct high-quality epidemiological studies in
Hong Kong26,29,30 and multinational pharmacovigilance
studies.31,32
Study Design
The self-controlled case series method is a case-only ap-
proach for eliminating between-person confounding. It com-
pares the rate of outcomes in riskperiodswithbaselinewithin
individuals, derived from cohort methodology.33 The analy-
sis is based on individualswhomust have had both the expo-
sure and the event. In Hong Kong, H pylori infection is diag-
nosed during endoscopy by rapid urease test or histologic
analysis before treatment, andempirical therapy is not a com-
monpractice. In this study, the exposure of interestwasHpy-
lori therapy containing clarithromycin in the outpatient set-
ting. We defined it as coprescription of clarithromycin with
either amoxicillin or metronidazole and one of the PPIs with
British National Formulary recommended doses (eTable 1 in
theSupplement)because therearenoother indications for this
coprescription. The coprescriptionsmust share the samepre-
scriptionstartdatewithanoverlappingdurationof7 to 14days.
We estimated the treatment duration by adding 1 day to the
differenceofprescriptionenddate andprescription start date.
The applicationof a strict definition increases theprecisionof
identifying suchexposure toavoid introducingbias fromiden-
tifying other acute infection indications.
Key Points
Question Is there an association between the use ofHelicobacter
pylori therapy containing clarithromycin and acute
neuropsychiatric events?
Findings In this study of 66 559 patients, 1824 patients receiving
H pylori treatment with clarithromycin had an incident
neuropsychiatric event, a 4-fold statistically significant increase
during a 14-day treatment period. The risk was not raised before
treatment and returned to baseline incidence after treatment.
Meaning The risk of neuropsychiatric events during the use ofH
pylori treatment with clarithromycin is short-term and will usually
resolve after cessation of treatment and psychiatric intervention
can be avoided.
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The primary outcome was the first recorded acute com-
posite neuropsychiatric events, while secondary outcomes
were the first recorded psychotic events and first recorded
cognitive impairment as principal diagnosis for an inpatient or
accident and emergency admission. All cases were identified
according to the International Classification of Diseases, Ninth
Revision (ICD-9) (eTable 2 in the Supplement). Based on the
symptoms (ie, psychosis, delirium, mood, and sleep distur-
bances) described in the identified case reports,19-25 a list of
diagnostic codes that describes acute and possibly drug-
induced clinical conditions for neuropsychiatric events was
developed and independently reviewed by 2 local clinical
psychiatrists (E.H.M.L. and W.C.C.). To enhance the reliability
and validity of the case definition, a final list of diagnostic
codes was then confirmed by consensus in meetings involv-
ing psychiatrists and researchers.
Patients who were at least 18 years old and had received
at least 1 outpatient prescription ofH pylori therapy contain-
ing clarithromycin during the study period (from January 1,
2003, toDecember31, 2012)were identified. If therewasapre-
ceding gap ofmore than 7 dayswith no prescription, this was
defined as a newprescription. To remove those patients with
more severe health issues identified on the prescription date,
patients who received any clarithromycin prescription or in-
patient therapy prior to the first outpatient therapy were ex-
cluded. Follow-up was censored if patients received a clar-
ithromycin prescription or inpatient therapy after the first
outpatient therapy.ThiscohortofpatientswithHpylori therapy
containing clarithromycinwas also described in our previous
publication.26
The observation period (Figure) started 1 year after pa-
tients entered thedatabase, and follow-upwas censoredat the
study end date, death, or any censoring events described
herein. Because treatment duration for each prescription
ranged from 7 to 14 days, 2 risk periods were defined as fol-
lows: current use (days 1-14 since prescription start date) and
recent use (days 15-30). To correct the estimates if the expo-
sures are event dependent, we also separated a 14-day preex-
posure period from the baseline. This could address bias re-
sulting from change in baseline incidence in the period just
before the exposure if the event alters the likelihood of sub-
sequent exposure.
Statistical Analyses and Sensitivity Analyses
Incidence rate ratios (IRRs)withageadjustment in singleyears
wereestimatedusing theconditional Poisson regression, com-
paring the rate of events during risk periods with that during
baseline.
Because events identified on the first day of prescription
might reflect theunderlyinghealth statusof thepatient rather
than being induced by the therapy of interest, we conducted
a sensitivity analysis by either removing the first day of pre-
scription from current use of treatment or including it in the
preexposureperiod (ie,weconsideredonlydays2-14).Wecar-
ried out additional sensitivity analysis to divide current use
into 2 periods (days 1-7 and days 8-14). Another sensitivity
analysis was conducted to include other ICD-9 codes, which
have nonspecific descriptions for psychotic events to test the
robustness of the outcome identification (eTable 2 in the
Supplement). Because metronidazole has infrequently been
reported tobeassociatedwithneuropsychiatric events,34-37we
conducted additional sensitivity analyses that included pa-
tientswithHpylori therapycontaining clarithromycin, amoxi-
cillin, and PPIs only.
We estimated the crude absolute risk with 95% CIs for all
outcomesas thenumberof eventsoccurredduringcurrentuse
Figure. Study Analyses
Baseline
period
14-Day preexposure
period
Current use
(Days 1-14 since
prescription start date)
Recent use
(Days 15-30 since
prescription start date)
Current exposure period
(Days 1-14 on or prior
to index date)
Recent exposure period
(Days 15-30 prior
to index date)
Self-controlled case series analysisA
End of 
prescription
End of further
prescription
Initiation of
prescription
Initiation
of further
prescription
End of
observation
period
Start of
observation
period
Index date
(event occurrence)
Case
Controls
Day 30 Day 1
Nested case-control analysisB
A, The observation period started 1
year after patients entered the
database, and follow-up was
censored at the study end date,
death, or any censoring events. Two
risk periods were defined as follows:
current use (days 1-14 since
prescription start date) and recent
use (days 15-30). To correct the
estimates if the exposures are event
dependent, we also separated a
14-day preexposure period from the
baseline. B, The follow-up started
from the date of first outpatient
prescription until study end date,
death, occurrence of event, or any
censoring events described in the
self-controlled case series analysis.
We defined current and recent
exposure periods similar to the
self-controlled case series analysis.
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divided by the total number of identified outpatientH pylori
therapy containing clarithromycin.30
A post hoc nested case-control analysis among patients
withoutpatientHpylori therapycontainingclarithromycinwas
conducted to validate the findings of the primary outcome in
the self-controlled case series analysis. Patients were eligible
if theywere at least 18 years old at the prescription start date.
Follow-up commenced from the date of first outpatient pre-
scription until study end date, death, occurrence of event, or
any censoring events described in the self-controlled case se-
ries analysis.We identified caseswithin the study period and
then randomlymatched4controls atmost toeachcasebyyear
of birth and sexusing the incidencedensity samplingmethod.
Wedefined current and recent exposureperiods similar to the
self-controlled case series analysis (Figure). Only the current
exposure period was considered if the prescription spanned
the current and recent exposureperiods.Using conditional lo-
gistic regression, we estimated the crude and adjusted odds
ratioswithadjustedvariablesofpsychiatric serviceuse inpub-
lic sector and the use of other drugs (diuretics, calcium chan-
nel blockers, bronchodilators, psychotropicdrugs, antiepilep-
tic drugs, antiparkinsonian drugs, antiretroviral drugs, oral
corticosteroids, andnonsteroidal anti-inflammatorydrugs) in
the previous 365 days prior to the event.
The statistical analyseswere conducted independentlyby
2 investigators (A.Y.S.W. andC.S.L.C.) for quality assurance.All
statistical analyses were performed with the use of SAS soft-
ware (version9.3; SAS Institute Inc) andR (version3.2.0; http:
//www.R-project.org).
Results
A total of 66 559 patients who were at least 18 years old and
had received at least 1 outpatient prescription of H pylori
therapycontainingclarithromycinduringthestudyperiodwere
identified. Theirmean (SD) age at cohort entrywas 50.8 (14.8
years); their mean age at first exposure was 55.4 (14.8) years,
and 30910 were male (46.4%). A total of 1824 patients were
identified with a first recorded composite neuropsychiatric
event (eFigure 1 in the Supplement), 354with a first recorded
psychotic event, and 726 with a first recorded cognitive im-
pairment within the study period (Table 1). eTable 3 in the
Supplement shows the top 3 most frequently reported diag-
nostic codes for each outcome.
Table 2 shows the IRRs of all outcomes. Comparing cur-
rent use with the baseline, the IRR for composite neuropsy-
chiatric events was 4.12 (95%CI, 2.94-5.76) (35 events during
72 person-years) andwas reduced to 0.95 (95%CI, 0.49-1.83)
during recent use (9 events during 82 person-years). No in-
creased risk couldbe foundduring thepreexposureperiod (14
events during 72 person-years) vs baseline (1766 events dur-
ing 16665 person-years). For psychotic events, an increased
IRRof 5.42 (95%CI, 2.77-10.60)was foundduring current use
(9 events during 14person-years) but not in other risk periods
vs baseline. The risk of cognitive impairmentwas nearly 2- to
3-fold higher during current use (9 events during 28 person-
years; IRR, 2.63 [95% CI, 1.36-5.09]), but there was no evi-
dence of increased risk for all other risk periods. Similar to the
primary analyses, increased IRRswere also foundduringdays
2 to 14since theprescriptionstartdate forall outcomesvsbase-
Table 1. Demographic Information of the Final Cohort of the Included
Patients
Characteristic
Composite
Neuropsychiatric
Events
Psychotic
Events
Cognitive
Impairment
Patients receiving
therapy, No.
1824 354 726
Age, mean (SD), y
At cohort entry 54.4 (15.8) 55.4 (17.3) 61.6 (14.6)
At exposure 59.1 (15.6) 59.8 (16.8) 66.2 (14.2)
At time of event 59.8 (16.2) 60.9 (17.7) 67.6 (14.8)
Male sex, No. (%) 833 (45.7) 170 (48.0) 394 (54.3)
Table 2. Results of Self-controlled Case Series Analysis for the Use ofHelicobacter pylori Therapy Containing
Clarithromycin and Risk of Neuropsychiatric Events
Type of Event Person-years Events, No. Age-Adjusted IRR (95% CI)
Composite neuropsychiatric events
(n = 1824)
Baseline 16 665 1766 NA
14 Days before prescription 72 14 1.63 (0.96-2.77)
Days 1-14 since prescription start date 72 35 4.12 (2.94-5.76)
Days 15-30 since prescription start date 82 9 0.95 (0.49-1.83)
Psychotic events (n = 354)
Baseline 3117 340 NA
14 Days before prescription 14 3 1.78 (0.57-5.56)
Days 1-14 since prescription start date 14 9 5.42 (2.77-10.60)
Days 15-30 since prescription start date 16 2 1.09 (0.27-4.40)
Cognitive impairment (n = 726)
Baseline 6583 705 NA
14 Days before prescription 29 6 1.71 (0.76-3.82)
Days 1-14 since prescription start date 28 9 2.63 (1.36-5.09)
Days 15-30 since prescription start date 32 6 1.56 (0.70-3.50) Abbreviations: IRR, incidence rate
ratio; NA, not applicable.
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line (eTables4and5 in theSupplement). The sensitivity analy-
sis in which current use was divided into days 1 to 7 and days
8 to 14 still showedan increased risk for primaryoutcomeand
psychotic events. For cognitive impairment, an increased risk
was observed from days 1 to 14 but not for days 1 to 7. The in-
significant finding for the former periodwas likely due to un-
stable estimates resulting from small sample size (eTable 6 in
the Supplement). After including thenonspecific ICD-9 codes
in thesensitivityanalysis, a similar temporalpatterncouldalso
beobserved (eTable7 in theSupplement).Foradditional analy-
ses that considered only therapy containing clarithromycin,
amoxicillin, and PPIs, increased risk during current use was
still observed for all outcomes (eTable 8 in the Supplement).
A total of 77 758 outpatient H pylori therapy containing
clarithromycin prescriptions were identified during the study
period. The crude absolute risk of neuropsychiatric events,
psychotic events, and cognitive impairment during current
use of therapy were 0.45 (95% CI, 0.32-0.63), 0.12 (95% CI,
0.06-0.22), and 0.12 (95% CI, 0.06-0.22) per 1000 prescrip-
tions, respectively.
Similar to self-controlled case series analysis,we found in-
creasedcrudeandadjustedodds ratiosduring treatment in the
nested case-control analysis (eTables 9 and 10 in the Supple-
ment).
Discussion
Relative to baseline incidence, the incidence of neuropsychi-
atric events was approximately 4-fold higher during the cur-
rent use ofH pylori therapy containing clarithromycin. Nota-
bly, the risk returned to baseline incidence during recent use
of treatment, suggestingthat theriskofneuropsychiatricevents
is short-term. In our previous study,26wehighlighted the car-
diovascular safety issues of clarithromycin and recom-
mended that clarithromycin should be prescribed with cau-
tion in patients with high baseline cardiovascular risk. In this
study, however, given the lowabsolute neuropsychiatric risk,
an abrupt change in prescribing practice based on the ob-
served increase in neuropsychiatric events is not suggested,
particularly in the absence of better treatment alternatives.
Similar to our previous study,26 clinicians should also bewell
informedof transientneuropsychiatric events associatedwith
this treatment.Suchtransientneuropsychiatriceventswillusu-
ally resolve spontaneously after treatment cessation, andpsy-
chiatric interventions can be avoided.
Because the self-controlled case series analysis is suit-
able for investigating the associationbetween transient expo-
sure and acute outcome,33 thismethodwas used in our study
to eliminate time-invariant confounders. However, similar to
otherobservational studydesigns, it is still susceptible to time-
varyingconfounders, suchasashort-termchange inhealthsta-
tus and the use of other drugs. To address this, we further ad-
justed for the use of other drugs in the nested case-control
study analysis and found similar results.
Notably,acute infection (eg,pneumonia)might leadtosub-
stantial short-termincreased riskofneuropsychiatric events.38
BecauseHpylori is by nature a chronic infection, it is unlikely
to temporally change the incidenceofneuropsychiatric events
shortly before and after treatment initiation. Therefore, it is
less likely to lead to a spurious short-term association be-
tween therapy and outcome. Another considerationwas that
if theneuropsychiatric eventsweredue to the infection rather
than therapy, wewould have observed an increased risk dur-
ing thepreexposureperiod.Because thiswasnotobserveddur-
ing thepreexposureperiod in anyof the analyses,we can con-
clude that the short-term increased risk of neuropsychiatric
events ismore likely to be attributable to the therapy than the
infection itself.
Because we investigated H pylori therapy as the expo-
sure, we could not pinpoint which drug in the regimen con-
tributed to the neuropsychiatric events in our study. We hy-
pothesized that clarithromycin is the most probable drug
because very limited evidence suggested that neuropsychiat-
ric events are associatedwith amoxicillin39,40 or PPIs.41-43We
alsoconductedsensitivityanalyses to test the robustnessof the
result whenmetronidazole (for which there are some reports
of association with neuropsychiatric events compared with
other ingredients)34-37was removed fromtheanalysis. The in-
creased riskofneuropsychiatric eventsduring currentuse still
remained. In addition, a case report raised an interesting and
important case in which a patient who should have received
clarithromycin, lansoprazole,andamoxicillin forHpylorieradi-
cation inadvertently took ciprofloxacin instead of clarithro-
mycin for a week owing to a dispensing error. The neuropsy-
chiatric symptomsdidnot appearuntil 2 days after thepatient
changed back to the correct regimen (ie, clarithromycin).25
Moreover, all the identifiedcases remitted1 to3daysafter treat-
ment discontinuation in the current literature.19-25 Therefore,
clarithromycin is themost probable culprit to increase neuro-
psychiatric risk.Although thepotential effect of otherdrugs in
the regimencouldnotbeentirely ruledout, theevidence inour
study still suggests thatHpylori therapy containing clarithro-
mycin as a whole increases short-term neuropsychiatric risk.
This should be brought to the attention of prescribers. Fur-
ther research is needed to evaluate the neuropsychiatric risk
associated with different drugs in the regimen.
Whilemacrolides diffusion to the central nervous system
is considered to be poor,44 the mechanism pathway govern-
ing its neuropsychiatric adverse effect is still unknown. Sev-
eral explanationshavebeenpostulated, includingdirect toxic
effects on the central nervous system by the active metabo-
lite of clarithromycin (14-hydroxyclarithromycin), altera-
tions in the metabolism of cortisol, prostaglandin, and other
hormones associatedwithneuropsychiatric events, aswell as
interactions with neurotransmitters (glutamate and gamma-
aminobutyric acid).17,18 Further research is warranted to ex-
plore these hypotheses.
With reference to the temporal association and dosage,
our findings are consistent with the results of many potential
cases of clarithromycin-induced neuropsychiatric events,
which were summarized in a review.17 This review reported
that neuropsychiatric symptomsmanifested 1 to 10 days after
receiving clarithromycin treatment, which is in line with our
results. It also seems that high-dose clarithromycin (>1000
mg/d for treatment of Mycobacterium avium complex or
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Mycobacterium abscessus lung infection) is not a necessary
condition for neuropsychiatric events.3,17,18,45 In our study,
patients were prescribed the British National Formulary
usual recommended dose (1000mg/d or 500mg/d).
Toour knowledge, this is the first population-based study
investigating this associationusing the self-controlled case se-
ries method to eliminate any fixed residual confounding. In
addition,comprehensive linkagesbetweenpublichospitalsand
outpatient clinics health services provided accurate case as-
certainment in our database. Although the retrospective na-
ture of our study precludes us from conducting prospective
structured interviews toconfirmdiagnoses, inaccuracies in the
ascertainment of cases areminimized because the diagnostic
codes for each inpatient case in public hospitals inHongKong
are verified and input in a standardized format in the comput-
erized clinical management system by the treating clinician.
Weuseddischarge diagnoses for case identification to ensure
that a thoroughdiagnostic reviewhadbeenperformedby the
clinical team involving senior specialists and the treating cli-
nician. Previous studies using similar methods to ascertain
other clinical outcomes by the Clinical Data Analysis and Re-
porting System have reported high positive predictive values
for events such as gastrointestinal tract bleeding,29 myocar-
dial infarction,26 stroke,26 autismspectrumdisorders, and at-
tention-deficit/hyperactivity disorder (K. K.Man; email com-
munication; February 17, 2016). Moreover, if we assume the
likelihood of diagnostic inaccuracy was the same during the
risk period and baseline, this error would underestimate the
association and increase the likelihood of a negative finding.
Our study is limited to patientswithHpylori infection; there-
fore, our findings are less generalizable to patients who have
been prescribed clarithromycin for other indications. An-
other limitation is thatwewerenot able todeterminedrug ad-
herence owing to limiteddata availability, and thismight lead
to some degree of bias frommisclassification of exposure. In
addition, clinical data fromprivate health care setting are not
available in ourdatabase.However,we includedpatientswho
used public health care services at least twice. These in-
cluded patients were very likely to use public health care ser-
vices insteadofprivate services, because thepublichealthcare
cost is heavily subsidized by the government.
Conclusions
This study found a short-term increased risk of neuropsychi-
atriceventsassociatedwithcurrentuseofHpylori therapycon-
taining clarithromycin, and the temporal increased risk is in
full concordancewith the treatment duration. Such transient
neuropsychiatric eventswill usually resolve spontaneously af-
ter treatment cessation and psychiatric interventions can be
avoided.
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